Hospital

The data follow the FDA approval of omalizumab for the reduction of allergic reactions, including anaphylaxis, that can occur after exposure to 1 or more foods.

The results were presented as a late-breaking poster presentation at the American Academy of Allergy, Asthma, and Immunology Annual Meeting.

The new indication includes individuals with HIV who have suppressed viral loads with known or suspected M184V/I resistance.

Investigators found genetic evidence that certain sleep behaviors can be risk factors for lifespan.

“I’m better than I was before I had long COVID, and in so many ways,” said a patient in an interview with Pharmacy Times.

The withdrawal comes after clinical trial results failed to demonstrate the safety and efficacy of melphalan flufenamide when combined with dexamethasone.

The recommendation comes after positive phase 3 trial results in adult patients with relapsed and refractory multiple myeloma.

The evolution of pharmacy, as a practice and profession, is unique in that its evolution has quickened exponentially in just the past 20 years.

Currently, the safety and efficacy of linvoseltamab in adult patients with relapsed or refractory multiple myeloma is being compared to elotuzumab, pomalidomide, and dexamethasone in a phase 3 clinical trial.

Investigators suggested that this difference is caused by a common medication for treatment-resistant schizophrenia.

Malaria has a large global burden, affecting hundreds of millions of people each year.

Teclistamab was previously approved in October 2022 for the treatment of adult patients with relapsed or refractory multiple myeloma who received at least 4 prior therapies.

Smoking 20 cigarettes per day significantly increased risk of death caused by certain types of melanomas.

Datopotamab deruxtecan is an investigational TROP2 directed antibody drug conjugate that showed positive survival impact compared to chemotherapy.

If vorasidenib receives full approval, it would be a first-in-class target therapy to treat individuals with IDH-mutant gliomas.

However, increasing dietary niacin did not reduce risk of mortality from cardiovascular disease, the primary cause of death associated with nonalcoholic fatty liver disease.

Living organisms rely on iron for survival and replication. Can new research discoveries disrupt C. difficile’s ability to maintain iron homeostasis?

Targeted use of ultraviolet light and sporicidal treatment can reduce disease transmission alongside existing interventions.

Cardioprotective antihyperglycemic agents are underutilized for inpatient care in heart failure patients. Lack of use can lead to preventable patient deaths and hospital readmissions.

The pharmacist’s role may vary across different practices and institutions.

This marks omalizumab’s fourth FDA-approved indication for allergic and inflammatory conditions, such as severe persistent allergic asthma, with its initial approval being in 2003.

Tigilanol tiglate is a novel, small molecule drug for the intratumoral treatment of solid tumors, inducing tumor cell death and stimulating immune response.

Sustained cognitive improvement is likely a result of lower inflammation, remission of comorbidities, higher physical activity, and better mood.

The investigators note that patients with newly diagnosed multiple melanoma who receive quadruplet treatment have unmet needs that must be further examined in future research.

The authors emphasize that further research on a diverse population that focuses on the role of duration and lifestyle choices and neuroinflammatory markers should be performed.

Nutrition is foundational to health, but healthy eating does not look the same for everyone.

The researchers made a connection between positive outcomes for infectious disease patients, higher reimbursement class, and the presence of pharmacists in care teams.

The approval of irinotecan liposome offers an improved first-line treatment option for individuals diagnosed with metastatic pancreatic adenocarcinoma.

Iloprost had also received Priority Review and Orphan Drug Designations for this indication, and FDA approval in 2004 for the treatment of pulmonary arterial hypertension.

Continued doses of denosumab reduced the incidence of diabetes by more than 1000 patients compared to an initial dose alone.